You are viewing: Belgium Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The Belgium Leukapheresis Market was valued at $0.58 Million in 2026 and projected to reach to $0.8 Million by 2031, representing a compound annual growth rate of CAGR 6.7%. Belgium's leukapheresis market demonstrates steady growth potential driven by increasing hematologic malignancy prevalence and expanding CAR-T cell therapy programs across major Belgian medical centers.

Belgium Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Belgium Leukapheresis Market Trends and Insights

  • Belgium's healthcare infrastructure supports the adoption of advanced cell separation technologies, with increasing demand driven by rising hematologic malignancy cases and expanded CAR-T cell therapy access across Belgian medical centers.
  • The market reflects Belgium's commitment to precision medicine and immunotherapy innovation within the European healthcare landscape. Growth in Belgium's leukapheresis market is underpinned by enhanced reimbursement policies, growing clinical trial activity, and improved patient access to apheresis procedures in Belgium's specialized treatment facilities.
  • Belgium continues to strengthen its position as a hub for cellular immunotherapy, with healthcare providers investing in state-of-the-art leukapheresis equipment to support both therapeutic and research applications.
  • Between 2026 and 2031, Belgium is expected to see steady market expansion as awareness of leukapheresis benefits increases among oncologists and hematologists..

Key Market Statistics

  • CAGR (2026-2031) CAGR 6.7%
  • Market Size, 2026 ~USD 0.58 Million
  • Forecast, 2031 ~USD 0.8 Million
  • Country Belgium

Belgium Leukapheresis Market Overview

Market Size & Growth :

Belgium's leukapheresis market is valued at $0.58 million in 2026, expanding to $0.80 million by 2031 at a CAGR of 6.7%, outpacing many European peers in adoption rates.

Healthcare Infrastructure Advantage :

Belgium's advanced healthcare system and well-established medical centers provide strong support for implementing cutting-edge cell separation technologies and leukapheresis procedures.

CAR-T Cell Therapy Expansion :

Increased accessibility to CAR-T cell therapies across Belgian medical institutions is driving demand for leukapheresis services as a critical preparatory procedure for immunotherapy treatments.

Rising Hematologic Malignancy Cases :

Growing incidence of blood cancers and leukemia in Belgium is fueling demand for advanced cell separation technologies and leukapheresis procedures in oncology centers.

Belgium Leukapheresis Market Dynamics

  • The country's robust healthcare infrastructure and high adoption rates of advanced medical technologies position it favorably for market expansion through 2031. Key growth drivers include rising patient awareness, improved reimbursement policies for cell therapy procedures, and investments in specialized oncology and hematology departments.
  • Belgium's strategic location within Europe and integration with international healthcare networks further support market development and technology adoption among healthcare providers..

Related Ecosystem

Key Takeaways

  • Belgium's leukapheresis market is valued at $0.58 million in 2026 and will reach $0.80 million by 2031 at a 6.7% CAGR.
  • Belgium's advanced healthcare system and CAR-T cell therapy infrastructure drive demand for leukapheresis procedures.
  • Reimbursement improvements and clinical trial expansion are accelerating market growth across Belgium.
  • Belgium is positioned as a key European center for cellular immunotherapy and precision medicine innovation.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

Belgium Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

Target Audience

  • Medical Device Manufacturers : Leukapheresis equipment and cell separation technology providers need Belgium-specific market data to assess market potential, identify distribution partners, and develop localized product strategies.
  • Healthcare Providers & Hospitals : Belgian oncology centers, hematology departments, and CAR-T therapy centers require market insights to justify capital investments in leukapheresis equipment and plan service expansion.
  • Pharmaceutical & Biotech Companies : CAR-T cell therapy developers and immunotherapy manufacturers need Belgium market intelligence to understand patient populations, treatment adoption rates, and commercial opportunities.
  • Healthcare Consultants & Advisors : Management consulting firms and healthcare strategy advisors serving Belgian clients require accurate market data to support investment decisions and strategic planning initiatives.
  • Healthcare Investors & Private Equity : Investment firms evaluating opportunities in Belgian healthcare infrastructure and medical technology need market-specific data to assess growth potential and valuation metrics.

Key Companies in the Belgium Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Belgium-Specific Market Sizing : Obtain precise market valuation data for Belgium ($0.58M in 2026) with detailed forecasts through 2031, enabling accurate budget allocation and market entry strategies tailored to this specific geography.
  • Competitive Landscape Intelligence : Understand Belgium's unique competitive dynamics, key market players, and their positioning within the country's healthcare system to identify partnership and expansion opportunities.
  • Regulatory & Reimbursement Insights : Access Belgium-specific regulatory requirements, reimbursement frameworks, and healthcare policies affecting leukapheresis adoption and pricing strategies in the Belgian market.
  • Growth Driver Analysis : Identify Belgium-specific factors driving 6.7% CAGR growth, including CAR-T therapy expansion, rising malignancy cases, and healthcare infrastructure investments unique to the Belgian context.
  • Strategic Market Entry Planning : Develop informed go-to-market strategies for Belgium with localized insights on hospital networks, procurement processes, and key decision-makers in Belgian medical institutions.

Frequently asked questions

What is the current size of Belgium's leukapheresis market?

Belgium's leukapheresis market is estimated at $0.58 million in 2026.

What is the projected market size for Belgium by 2031?

Belgium's leukapheresis market is forecast to reach $0.80 million by 2031.

What is the CAGR for Belgium's leukapheresis market?

Belgium's leukapheresis market is expected to grow at a compound annual growth rate of 6.7% from 2026 to 2031.

What factors are driving growth in Belgium's leukapheresis market?

Key drivers include increased CAR-T cell therapy adoption, improved reimbursement policies, growing clinical trial activity, and rising hematologic malignancy cases in Belgium.

How does Belgium's market compare to other European countries?

Belgium maintains a specialized leukapheresis market supported by advanced healthcare infrastructure and strong immunotherapy research capabilities within the European region.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status